News

Results from two phase III trials, named ACT1 and ACT2, reveal that, among patients with moderate to severe active ulcerative colitis (UC) who experienced an inadequate response to

Under the terms of the amendment and consent agreement, certain provisions of Indevus’ license, commercialization and supply agreement, originally with Odyssey Pharmaceuticals, a subsidiary of Pliva, have been

The drug candidates are small molecule inhibitors of the hepatitis C virus (HCV) NS3/4 protease. These molecules, which have been shown previously to be highly potent, metabolically stable

These restructuring plans, which would include the loss of 63 jobs including the company’s entire dental sales force, follow the FDA approval of generic version of Periostat (doxycycline

Following treatment with Introgen’s experimental cancer vaccine, 67% of the evaluable patients in the study had objective responses (greater than 50% tumor reduction) to subsequent chemotherapy. Historically, the

This study adds to the established data on Toprol-XL (metoprolol succinate) in the treatment of hypertension in adults. Hypertension affects one in three adults and approximately one in

Xcyte said it will shift further clinical development of its lead product, Xcellerated T Cells, to focus on treating HIV. The company intends to submit an investigational new

As well as having shown potential in the treatment of phenylketonuria (PKU), there is preliminary clinical evidence that suggests that the active ingredient in Phenoptin (sapropterin hydrochloride), a

The new tool is designed to provide access to all data made available by the research-based pharmaceutical industry on clinical trial registries and databases around the world. “Disclosure